muscle stem cell

NNMTi (5-Amino-1-methylquinolinium) is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM; 50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathway

Fluacrypyrim is an ester-based acaricide and functions as a STAT3 inhibitor. It significantly enhances the activity of protein tyrosine phosphatases (PTPs) and suppresses leukemia cell growth by inducing substantial G1 phase arrest and significantly reducing the levels of cyclin D1 protein and mRNA. Fluacrypyrim selectively inhibits the STAT3 signaling pathway, leading to growth arrest and apoptosis in STAT3-dependent cancer cells. It mainly alleviates radiation-induced hematopoietic system damage by preventing apoptosis in hematopoietic stem cells (HSCs). Additionally, fluacrypyrim exhibits notable analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses.

MF-DH-300 is a 15-PGDH inhibitor with an IC50 of 1.6 nM. It blocks the interaction between 15-PGDH and PGE2, promoting stem cell proliferation, increasing muscle strength, and enhancing mitochondrial function. Additionally, MF-DH-300 raises the expression of survival motor neuron (SMN) protein and is applicable in research on muscle diseases such as spinal muscular atrophy (SMA).

Two Rho-associated kinases (ROCK), ROCK-I and ROCK-II, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. Glycyl-H-1152 is a selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK-II). It is a glycylated isoquinoline compound derived from the therapeutically-important ROCK inhibitor HA-1077 (Fasudil) and exhibits better specificity. Thus, it poorly inhibits Ca2+/calmodulin-dependent kinase type II, protein kinase (PK) G, and Aurora A (IC50 = 2.57, 2.35, and 3.26 μM, respectively) as well as PKA or PKC (IC50 ≥ 10 μM for each). The potency of Glycyl-H-1152 is superior to that of other ROCK inhibitors, including Y-27632 (Ki = 220 nM) and HA-1077 (IC50 = 158 nM).